TVTX
Travere Therapeutics Inc
NASDAQ: TVTX · HEALTHCARE · BIOTECHNOLOGY
$40.10
-1.93% today
Updated 2026-04-29
Market cap
$3.70B
P/E ratio
—
P/S ratio
7.55x
EPS (TTM)
$-0.57
Dividend yield
—
52W range
$14 – $43
Volume
1.9M
Travere Therapeutics Inc (TVTX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$40.10
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$61.58
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.1B | $0.2B | $0.5B |
| EPS | — | — | — | — | — |
CAGR applied: — (capped 20%) · P/E: 25.00x (capped 25x) · Margin: -5.21%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.